Relationship Between Heart Failure and Lipids: The Paradigm Continues to Evolve

Journal of Cardiac Failure

Volumn 13, Issue 4, 2007, Pages 254-258

  Giamouzis, Grigorios ^a,b   Butler, Javed ^a  

^a EMORY UNIVERSITY   (United States)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; SCAVENGER RECEPTOR BI; VERY LOW DENSITY LIPOPROTEIN;

CELL SURFACE; CHOLESTEROL METABOLISM; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EDITORIAL; HEART FAILURE; HUMAN; INFLAMMATION; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE;

ANIMALS; APOLIPOPROTEINS; BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 34248550464     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.03.009     Document Type: Editorial

References (43)

1. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., and Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001) 789-795
2. Horwich T.B., Hamilton M.A., Maclellan W.R., and Fonarow G.C. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 8 (2002) 216-224
3. Gheorghiade M., Abraham W.T., Albert N.M., Greenberg B.H., O'Connor C.M., She L., et al. OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
4. Kalantar-Zadeh K., Block G., Humphreys M.H., and Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003) 793-808
5. Chang A.K., Barrett-Connor E., and Edelstein S. Low plasma cholesterol predicts an increased risk of lung cancer in elderly women. Prev Med 24 (1995) 557-562
6. Haider A.W., Larson M.G., Franklin S.S., and Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 138 (2003) 10-16
7. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
8. Schillaci G., Vaudo G., Reboldi G., Verdecchia P., Lupattelli G., Pasqualini L., et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 19 (2001) 2265-2270
9. Horio T., Miyazato J., Kamide K., Takiuchi S., and Kawano Y. Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension. Am J Hypertens 16 (2003) 938-944
10. Krum H., and McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcomes trial?. J Am Coll Cardiol 39 (2002) 157-173
11. Iwaoka M., Obata J., Abe M., Nakamura M., Kitta Y., Kodama Y., et al. Association of low serum levels of apolipoprotein a-i with adverse outcomes in patients with non-ischemic heart failure. J Card Fail 13 (2007) 247-253
12. Marcovina S., and Packard C.J. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 259 (2006) 437-446
13. Koppaka V., and Axelsen P.H. Lipoprotein A-I structure. Trends Cardiovasc Med 9 (1999) 192-195
14. Barter P.J., and Rye K.A. The rationale for using apoA-I as a clinical marker of cardiovascular risk. J Intern Med 259 (2006) 447-454
15. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
16. Munger M.A., Johnson B., Amber I.J., Callahan K.S., and Gilbert E.M. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 77 (1996) 723-727
17. Suleiman M., Khatib R., Agmon Y., Mahamid R., Boulos M., Kapeliovich M., et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47 (2006) 962-968
18. De Denus S., White M., Tardif J.C., Bourassa M.G., Racine N., Levesque S., et al. Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction. J Card Fail 12 (2006) 353-359
19. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987-1994
20. Ashby D., Gamble J., Vadas M., Fidge N., Siggins S., Rye K., et al. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis 154 (2001) 113-121
21. Ashby D.T., Rye K.A., Clay M.A., Vadas M.A., Gamble J.R., and Barter P.J. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol 18 (1998) 1450-1455
22. Dimayuga P., Zhu J., Oguchi S., Chyu K.Y., Xu X.O., Yano J., et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 264 (1999) 465-468
23. Rong J.X., Li J., Reis E.D., Choudhury R.P., Dansky H.M., Elmalem V.I., et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 104 (2001) 2447-2452
24. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005) 1543-1550
25. Cockerill G.W., McDonald M.C., Mota-Filipe H., Cuzzocrea S., Miller N.E., and Thiemermann C. High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock. Faseb J 15 (2001) 1941-1952
26. Paterno R., Ruocco A., Postiglione A., Hubsch A., Andresen I., and Lang M.G. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 17 (2004) 204-211
27. McDonald M.C., Dhadly P., Cockerill G.W., Cuzzocrea S., Mota-Filipe H., Hinds C.J., et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20 (2003) 551-557
28. Cockerill G.W., Huehns T.Y., Weerasinghe A., Stocker C., Lerch P.G., Miller N.E., et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 103 (2001) 108-112
29. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
30. Bisoendial R.J., Hovingh G.K., Levels J.H., Lerch P.G., Andresen I., Hayden M.R., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003) 2944-2948
31. Garner B., Witting P.K., Waldeck A.R., Christison J.K., Raftery M., and Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 273 (1998) 6080-6087
32. Garner B., Waldeck A.R., Witting P.K., Rye K.A., and Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273 (1998) 6088-6095
33. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ Res 95 (2004) 764-772
34. Charlton-Menys V., and Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 259 (2006) 462-472
35. Gotto Jr. A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary -Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
36. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
37. Walldius G., Aastveit A.H., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
38. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
39. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107 (2003) 1486-1491
40. Anand I.S., Latini R., Florea V.G., Kuskowski M.A., Rector T., Masson S., et al., Val-HeFT Investigators. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112 (2005) 1428-1434
41. Petersen J.W., and Felker G.M. Inflammatory biomarkers in heart failure. Congest Heart Fail 12 (2006) 324-328
42. Ware J.H. The limitations of risk factors as prognostic tools. N Engl J Med 355 (2006) 2615-2617
43. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 (2006) 2631-2639